ZMAT3 and cancer: Additional support for the idea that in addition to the absence of ZMAT3, additional TP53/TRP53-regulated processes must also be disabled for spontaneous tumour development comes from the observation that mutations in ZMAT3 are not prevalent in human cancers compared to the very high frequency of TP53 mutations [6, 46].